The U.S. Food and Drug Administration (FDA) expanded the approved use of Stivarga® (regorafenib)to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed... Continue Reading

A large proportion of cancer patients do not enroll in clinical trials, and those who do participate may not adequately represent age groups, cancer stages, cancer types, and racial and ethnic groups.... Continue Reading

Treatment with Gleevec® (imatinib) for 3 years following surgery significantly improves survival compared with the standard one-year therapy for patients with gastrointestinal stromal tumors (GIST). GIST... Continue Reading

Among patients with gastrointestinal stromal tumors (GIST) that were resistant to both Gleevec® (imatinib) and Sutent® (sunitinib), treatment with Nexavar® (sorafenib) resulted in tumor shrinkage or... Continue Reading

Gleevec® Approved for Adjuvant Treatment of Gastrointestinal Stromal Tumors The U.S. Food and Drug Administration has expanded the approval of Gleevec® (imatinib mesylate) to include the adjuvant (post-surgery)... Continue Reading

Update in the Management of Gastrointestinal Stromal Tumors (GIST): A Report from ASCO 2007 June 1-4, 2007 Chicago, IL Margaret von Mehren, MD Director Sarcoma Oncology, Fox Chase Cancer Center, Philadelphia,... Continue Reading

Gleevec® Confirmed as Effective Treatment for Early GIST According to results from a large North American clinical trial, Gleevec® (imatinib mesylate) reduces the risk of a cancer recurrence following... Continue Reading

Interruption of Treatment with Gleevec® Not Recommended for GIST According to an article published in the Journal of Clinical Oncology, interruption in treatment with Gleevec® (imatinib mesylate) is... Continue Reading

Two-gene Test Correctly Distinguishes GIST from Leiomyosarcoma According to the results of a study published in the Proceedings of the National Academy of Sciences, a test that assesses the expression... Continue Reading

Sutent® Improves Outcomes for Patients with GIST According to an article recently published in The Lancet, Sutent® (sunitinib) improves outcomes among patients with gastrointestinal stromal tumor (GIST)... Continue Reading